Richard Maziarz
Expertise in
26
conditions

Dr. Richard Maziarz

Hematology
OHSU Hospital
3181 SW Sam Jackson Park Rd, 
Portland, OR 
Offers Telehealth
43 Years of Experience
Expertise in
26
conditions
OHSU Hospital
3181 SW Sam Jackson Park Rd, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Maziarz is a Hematologist in Portland, Oregon. Dr. Maziarz has been practicing medicine for over 43 years is highly rated in 26 conditions, according to our data. His top areas of expertise are B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 208 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in OR
Hospital Affiliations
Ohsu Hospital And Clinics
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

OHSU Hospital
3181 SW Sam Jackson Park Rd, Portland, OR 97239
Other Locations
University Andrology Lab LLC
3303 S Bond Ave, Portland, OR 97239

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug, Biological
Study Drugs: SQZ-AAC-HPV, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Enrollment Status: Terminated
Publish Date: January 30, 2020
Intervention Type: Biological
Study Phase: Phase 3
View 10 Less Clinical Trials

209 Total Publications

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 18, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Stephen Forbes
Hematology
Expertise in
22
conditions
Dr. Stephen Forbes
Hematology

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (0.7 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Forbes is a Hematologist in Portland, Oregon. Dr. Forbes is highly rated in 22 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Michael Heinrich
Expertise in
18
conditions
Dr. Michael Heinrich
Hematology
Expertise in
18
conditions
Dr. Michael Heinrich
Hematology

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (0.7 miles away)
503-494-6594
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Heinrich is a Hematologist in Portland, Oregon. Dr. Heinrich is highly rated in 18 conditions, according to our data. His top areas of expertise are Gastrointestinal Stromal Tumor, Chronic Myelogenous Leukemia (CML), Mesenchymoma, and Undifferentiated Pleomorphic Sarcoma.

Expertise in
10
conditions
Dr. Ronan Swords
Hematology
Expertise in
10
conditions
Dr. Ronan Swords
Hematology

OHSU Knight Cancer Institute South Waterfront

3485 S Bond Ave, 
Portland, OR 
 (0.1 miles away)
503-494-7999
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ronan Swords is a Hematologist in Portland, Oregon. Dr. Swords is highly rated in 10 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Myeloproliferative Neoplasms (MPN), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Maziarz's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 15 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile